Aker Biomarine ASA
F:1PG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Aker Biomarine ASA
F:1PG
|
NO |
|
B
|
BlackRock Inc
F:UU2
|
US |
|
H
|
Humana Inc
XMUN:HUM
|
US |
|
F
|
Franklin Street Properties Corp
F:WVH
|
US |
|
Akzo Nobel NV
AEX:AKZA
|
NL |
|
E
|
Exor NV
DUS:EYX
|
NL |
|
M
|
Maven Brands Inc
XMUN:TLA
|
CA |
|
S
|
Silvercorp Metals Inc
XMUN:S9Y
|
CA |
|
L
|
Leifheit AG
F:LEI
|
DE |
|
M
|
Minor International PCL
SET:MINT
|
TH |
|
P
|
Peerapat Technology PCL
SET:PRAPAT
|
TH |
|
P
|
Prosper Engineering PCL
SET:PROS
|
TH |
|
Demant A/S
F:WDH1
|
DK |
|
ArcelorMittal SA
AEX:MT
|
LU |
|
Nevis Brands Inc
F:8DZ
|
US |
|
A
|
Assetwise PCL
SET:ASW
|
TH |
|
B
|
BP PLC
F:BSU
|
UK |
|
Inclusio SA
F:9ZS
|
BE |
|
LATAM Airlines Group SA
SGO:LTM
|
CL |
|
S
|
Shape Robotics A/S
CSE:SHAPE
|
DK |
|
Signify NV
AEX:LIGHT
|
NL |
Earnings Calls
Last Earnings Call
Revenue: Aker BioMarine reported second-quarter revenue of $57.9 million, up 5% year over year, with adjusted EBITDA of $12.9 million.
Human Health: Human Health Ingredients had a record quarter, with revenue up 17% and krill oil sales up 21% on stronger volume and better pricing.
Consumer Weakness: Consumer Health Products was soft, with revenue down 6% year over year, but management said new product launches should help it return to modest growth later in the year.
New Wins: The company announced a new Lysoveta contract in China and a new Superba business in the U.S., both seen as important steps for future growth.
Cost Pressure: EBITDA was held back by higher SG&A, lower QHP production in Houston, and the end of TSA income from the Qrill Company.
Outlook: Management expects Human Health Ingredients to keep improving and Consumer Health Products to recover as new products reach shelves, while net debt may rise further in Q3 because of Nutra payments.